The importance of neopterin as a laboratory diagnostic marker of immune activation

Pteridines

Volumn 10, Issue 3, 1999, Pages 101-111

  Widner, Bernhard ^a   Murr, Christian ^a   Wirleitner, Barbara ^a   Mayr, Christiane ^a   Spöttl, Nathalie ^a   Baier Bitterlich, Gabriele ^a   Fuchs, Dietmar ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; NEOPTERIN;

AUTOIMMUNE DISEASE; BACTERIAL INFECTION; CELLULAR IMMUNITY; DISEASE MARKER; GRAFT REJECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSTIMULATION; IMMUNOSURVEILLANCE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; VIRUS INFECTION;

BACTERIA (MICROORGANISMS); HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0032719119     PISSN: 09334807     EISSN: 21954720     Source Type: Journal    
DOI: 10.1515/pteridines.1999.10.3.101     Document Type: Article

References (108)

1. Huber C, Batchelor JR, Fuchs D, Hausen A, Lang A, Niederwieser D, Reibnegger, Swetly P, Troppmair J, Wachter H. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon gamma. J. Exp. Med. 1984; 160: 310-316.
2. Romani N, Widner B, Reider D, Ebner S, Fuchs D. Are dentritic cells a relevant source of neopterin production in clinical conditions? Pteridines 1999, in press.
3. Werner-Felmayer G, Werner ER, Fuchs D, Hausen A, Reibnegger G, Wachter H. Neopterin formation and tryptophan degradation by a human myelomonocytic cell line (THP-1). Cancer Res. 1990; 50: 2863-2867.
4. Werner-Felmayer G, Werner ER, Fuchs D, Hausen A, Reibnegger G, Wachter H. Tumor necrosis factor-alpha and lipopolysaccharide enhance interferon-induced tryptophan degradation and pteridine synthesis in human cells. Biol. Chem. Hoppe Seyler 1989; 370: 1063-1069.
5. Weiss G, Murr C, Zoller H, Haun M, Widner B, Ludescher C, Fuchs D. Modulation of neopterin formation and tryptophan degradation by Th1- and Th2-derived cytokines in human monocytic cells. Clin. Exp. Immunol. 1999; 116: 435-440.
6. Andersson J, Nagy S, Groth CG, Andersson U. Effects of FK506 and cyclosporin A on cytokine production studied in vitro at a single-cell level. Immunology 1992; 75: 136-42.
7. Wachter H, Fuchs D, Hausen A, Reibnegger G, Werner ER. Neopterin as a marker for activation of cellular immunity: immunologic basis and clinical application. Adv. Clin. Chem. 1989; 27: 81-141.
8. Fuchs D, Hausen A, Reibnegger G, Werner ER, Dierich MP, Wachter H. Neopterin as a marker for activated cell-mediated immunity: application in HIV infection. Immunol. Today. 1988; 9: 150-155.
9. Halliwell B, Murcia MA, Chirico S, Aruoma IO. Free radicals and antioxidants in food and in vivo: what they do and how they work. Crit. Rev. Food. Sci. Nutr. 1995; 35: 7-20.
10. Nathan CF, Murray HW, Wiebe ME, Rube BY. Identification of interferon-g as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J. Exp. Med. 1983; 158: 670-689.
11. Fuchs D, Baier-Bitterlich G, Wede I, Wachter H. Reactive oxygen and apoptosis. In: Oxidative stress and the molecular biology of antioxidant defense (ed. Scandalios J) Cols Spring Harbor Laboratory Press, New York 1997; 139-167.
12. Fuchs D, Sattler W Leblhuber F, Walli J, Widner B, Baier-Bitterlich G. Inverse relationship between alpha-tocopherol and neopterin concentrations in cerebrospinal fluid of patients with dementia. Pteridines 1999, in press.
13. Widner B, Baier-Bitterlich G, Wede I, Wirleitner B, Wachter H, Fuchs D. Neopterin: indicator of oxidative stress and part of the cytotoxic armature of activated macrophages in humans. Pteridines 1998; 9: 91-102.
14. Werner ER, Bichler A, Daxenbichler G, Fuchs D, Fuith LC, Hausen, Hetzel H, Reibnegger G, Wachter H. Determination of neopterin in serum and urine. Clin. Chem. 1987; 33: 62-66.
15. Mayersbach P, Augustin R, Schcnnach H, Fuchs D, Werner ER, Schönitzer D, Wachter H. Applicability of an enzyme-linked immunosorbent assay for neopterin detection for screening of blood donations. Pteridines 1994; 5: 49-54.
16. Hausen A, Fuchs D, König K, Wachter H. Determination of neopterin in human urine by reversed-pase high-performance liquid chromatography. J. Chromatogr. 1982; 227: 61-70.
17. Fuchs D, Hausen A, Reibnegger G, Werner ER, Dittrich P, Wachter H. Neopterin levels in long term hemodialysis. Clin. Nephrol. 1988; 177: 1-6.
18. Reibnegger G, Auhuber I, Fuchs D, Hausen A, Judmaier G, Prior C, Werner ER, Wachter H. Urinary neopterin levels in acute and viral hepatitis. Hepatology 1988; 8: 771-774.
19. Wilmer A, Nolchen B, Tilg H, Herald M, Pechlaner C, Judmaier G, Dietze O, Vogel W. Serum neopterin concentrations in chronic liver disease. Gut 1995; 7: 108-112.
20. Schennach H, Schoenitzer D, Fuchs D. Association between chronic hepatitic C virus infection and increased neopterin concentrations in blood donors. Clin. Chem. 1998; 44: 2225-2226.
21. Kern P, Rokos H, Ditrich M. Raised serum levels and imbalances of T-lymphocyte subsets in viral diseases, aquired immune deficiency and related lymphadenopathy syndromes. Biomed. Pharmacother. 1984; 38: 407-411.
22. Tilg H, Margreiter R, Scriba M, Marth C, Niederwieser D, Aulitzky W Spielberger M, Wachter H, Huber C. Clinical presentation of CMV infection in solid organ transplant recipients and its impact on graft rejection and neopterin excretion Clin. Transplantation 1987, 1: 37-43.
23. Griffin DE, Ward BJ, Jauregui E, Johnson RT, Vaisberg A. Immune activation during measles: interferon gamma and neopterin in plasma and cerebrospinal fluid in complicated and uncomplicated disease. J. Infect. Dis. 1990; 161: 449-453.
24. Reibnegger G, Fuchs D, Grubauer G, Hausen A, Wachter H. Neopterin excretion during incubation period, clinical manifestation and reconvalescence of viral infection. In: Biochemical and Clinical Aspects of Pteridines Vol. 3 (Pfleiderer W., Wachter H., Curtius H.C., eds) Walter de Gruyter, Berlin-New York, 1984; 433-447.
25. Zaknun D, Weiss G, Glatzl J, Wachter H, Fuchs D. Neopterin levels during acute rubella in children. Clin. Infect. Dis. 1993; 17: 521-522.
26. Wachter H., Hausen A., Graßmayr K. Erhöhte Ausscheidung von Neopterin im Harn von Patienten mit malignen Tumoren und mit Viruserkrankungen. Hoppe-Seylers Z. Physiol. Chem. 1979; 360: 1957-1960.
27. Popov J, McGraw T, Hofmann B, Vowels B, Shum A, Nishanian P, Fahey JL. Acute lymphoid changes and ongoing immune activation in SIV infection. J. Acquir. Immune Defic. Syndr. 1992; 5: 391-399.
28. Reinhardt B, Jaspert R, Niedrig M, Kostner C, L'age-Stehr J. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J. Med. Virol. 1998; 56: 159-167.
29. Fuchs D, Hausen A, Reibnegger G, Werner ER, Werner-Felmayer G, Wachter H. Distinct neopterin excretion patterns after vaccination. Pteridines 1992; 2: 147-149.
30. Hussey GD, Goddard EA, Hughes J, Ryon JJ, Kerran M, Carelse E, Strebel PM, Markowitz LE, Moodie J, Barron P, Latief Z, Sayed R, Beatty D, Griffin DE. The effect of Edmonston-Zagreb and Schwarz measles vaccines on immune response in infants. J. Infect. Dis. 1996; 173: 1320-1326.
31. Zangerle R, Schönitzer D, Fuchs D, Möst J, Dierich MP, Wachter H. Reducing HIV transmission by seronegative blood. Lancet 1992; 339: 130-131.
32. Gaines H, von Sydow MA, von Stedingk LV, Biberfeld G, Bottiger B, Hansson LO, Lundbergh P, Sonnerborg AB, Wasserman J, Strannegaard OO. Immunological changes in primary HIV infection. AIDS 1990; 4: 995-999.
33. Daar ES, Moudgil T, Meyer RD, Ho DD. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N. Engl. J. Med. 1994; 324: 961-964.
34. Fuchs D, Spira TJ, Hausen A, Reibnegger G, Werner ER, Werner-Felmayer G, Wachter. Neopterin as apredictive marker for disease progression in human immunodeficiency virus type 1 infection. Clin. Chem. 1989; 35: 1746-1749.
35. Fahey JL, Taylor JMG, Detels R, Hofmann B, Melmed R, Nishanian P, Giorgi JV The prognostic value of cellular and serological markers in infection with human immunodeficiency virus type 1. N. Engl. J. Med. 1990; 322: 166-172.
36. Clark SJ, Saag MS, Decker WD, Campbell-Hill S, Roberson JL, Veldkamp PS, Kappes JL, Hahn BH, Shaw GM. High titers of cytopathic virus in plasma in patients with symptomatic primary HIV-1 infection. N. Engl. J. Med. 1991; 324: 957-960.
37. Fauci AS. The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. Science 1988; 239: 617-622.
38. Cordiali-Fei P, Massa A, Prignano G, Pietravalle M, Alemanno L, Vitelli G, Palamara G, Giglio A, Gandolfo GM, Gentili G. Behaviour of several 'progression markers' during the HIV-Ab seroconversion period. Comparison with later stages J. Biol. Regul. Homeost. Agents 1992; 6: 57-64.
39. Fuchs D, Albert J, Asjö B, Fenyö EM, Reibnegger G, Wachter H. Association between serum neopterin concentration and in vitro replicative capacity HIV-1 isolates. J. Infect. Dis. 1989; 160: 724-725.
40. Melmed RN, Taylor JMG, Detels R, Bozorgmehri M, Fahey JL. Serum neopterin changes in HIV-infected subjects: indicator of significant pathology, CD4 T-cell changes, and the development of AIDS. J. Acquir. Immune Defic. Syndr. 1989; 2: 70-76.
41. Fuchs D, Banekovich M, Hausen A, Hutterer J, Reibnegger G, WErner ER, Gschnait FD, Dierich MP, Wachter H. Neopterin estimation compared with the ratio of T-cell subpopulations in persons infected with human immunodeficiency virus-1 Clin. Chem. 1988; 34: 2415-2417.
42. Baier-Bitterlich G, Fuchs D, Wachter H. Chronic immune stimulation, oxidative stress, and apoptosis in HIV infection. Biochem. Pharmacol. 1997; 53: 755-763.
43. Krämer A, Biggar RJ, Hampl H, Friedman RM, Fuchs D, Wachter H, Goedert JJ. Immunologic markers of progression to acquired immunodeficiency syndrome are time dependent and illness specific. Am. J. Epidemiol. 1992; 136: 71-80.
44. Krowka JF, Esner ML, Ascher MS, Sheppard HW. Lack of associations of chemotactic cytokines with viral burden, disease progression, or lymphocyte subsets in HIV-infected individuals. Clin. Immunol. Immunopathol. 1997; 85: 21-27.
45. Mellors JW, Kingsley LA, Rinaldo CR Jr, Todd JA, Hoo BS, Kokka RP, Gupta P. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann. Intern. Med. 1995; 122: 573-579.
46. Zangerle R, Fuchs D, Reibnegger G, Fritsch P, Wachter H. Markers of disease progression in intravenous drug users infected with HIV-1. AIDS 1991; 5: 985-991.
47. Zangerle R, Steinhuber S, Sarcletti M, Dierich MP, Wachter H, Fuchs D, Möst J. Serum-HIV RNA levels compared to soluble markers of immune activation to predict disease progression in HIV-1 infected individuals. Int. Arch. Allergy Immunol. 1998; 116: 228-239.
48. Gisslen M. Norkrans-G; Svennerholm-B; Hagberg-L et al.: The effect on human immunodeficiency virus type 1 RNA levels in cerebrospinal fluid after initiation of zidovudine or didanosine. J. Infect. Dis., 1997, 175: 434-437.
49. Hutterer J, Armbruster C, Wallner G, Fuchs D, Vetter N, Wachter H. Early changes of neopterin concentrations during treatment of human immunodeficiency virus infection with zidovudine. J. Infect. Dis. 1992; 165: 783-784.
50. Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, Jones M, Facey K, Whitacre C, McAuliffe VJ, Friedman HM, Merigan TC, Reichman RC, Hooper C, Corey L. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N. Engl. J. Med. 1996; 334: 1011-1017.
51. Brew BJ, Bhalla RB, Paul M, Gallardo H, McArthur JC, Schwartz MK, Price RW. Cerebrospinal fluid neopterin in human immunodeficiency virus type 1 infection. Ann. Neurol. 1990; 28: 556-560.
52. Griffin DE, McArthur JC, Cornblath DR. Neopterin and interferon-gamma in serum and cerebrospinal fluid of patients with HIV-associated neurologic disease. Neurology 1991; 41: 69-74.
53. Fuchs D, Chiodi F, Albert J, Asjö B, Hagberg L, Norkrans G, Reinegger G, Werner ER, Wachter H. Neopterin concentrations in cerebrospinal fluid and serum of individuals infected with HIV-1. AIDS 1989; 3: 285-288.
54. Reibnegger G, Boonpucknavig V, Fuchs D, Hausen A, Schmutzhard E, Wachter H. Urinary neopterin is elevated in patients with malaria. Trans Roy. Soc. Trop. Med. Hyg. 1984; 78: 545-546.
55. Kern P, Hemmer CJ, Van Damme J, Gruss HJ, Dietrich M. Elevated tumor necrosis factor alpha and interleukin-6 serum levels as markers for complicated Plasmodium falciparum malaria. Am. J. Med. 1989; 87: 139-143.
56. Picot S. Peyron F, Vuillez JP, Barbe G, Deloron P, Jacob MC, Chumpitazi B, Boudin C, Sheik Zakkiudin I, Ambroise Thomas P. Neopterin levels in plasma during a longitudinal study in an area endemic for malaria. Clin. Immunol. Immunopathol. 1993; 67: 273-276.
57. Brown AE, Webster HK, Teja-Isavadharm P, Keeratithakul D. Macrophage activation in falciparum malaria as measured by neopterin and interferon gamma. Clin. Exp. immunol. 1990; 82: 97-101.
58. Kern P, Horstmann RD, Dietrich M. Clinical resolvement of malaria infection parallels decrease of highly elevated serum neopterin level. In: Biochemical and Clinical Aspects of Pteridines, Vol. 4, (Pfleiderer W., Wachter H., Curtius H.C., eds) Walter de Gruyter, Berlin-New York, 1985; 341-345.
59. Zwingenberger K, Feldmeier H, Nogueira-Queiroz JA, Vergetti-Siqueira JG, Farias-Auto H, Alencar JE, Bienzle U. Liver involvement in human schistosomiasis mansoni. Assessment by immunological and biochemical markers. Parasitol. Res. 1988; 74: 448-455.
60. Fuchs D, Hausen A, Kofler, M, Kosanowski H, Reibnegger G, Wachter H. Neopterin as an index of immune response in patients with tuberculosis. Lung 1984; 162: 337-346.
61. Horak E, Gassner I, Sölder B, Wachter H, Fuchs D. Neopterin levels and pulmonary tuberculosis in infants. Lung 1998; 176: 337-334.
62. Hosp M, Elliot AM, Raynes JG, Mwinga AG, Luo N, Zangerle R, Pobee JOM, Wachter H, Dierich MP, McAdam KPWJ, Fuchs D. Neopterin, b2-microglobulin, and the acute phase proteins in HIV-1 seropositive and seronegative Zambian patients with tuberculosis. Lung 1997; 175: 265-275.
63. Schmutzhard E, Fuchs D, Hausen A, Reibnegger G, Wachter H. Is neopterin - a marker or cellmediated immune response - helpful in classifying leprosy? East Afr. Med. J. 1986; 63: 577-580.
64. Brown AE, Dance DAB, Chaowagul W, Webster HK, White NJ. Activation of cellular immune respoase in melioidosis patients as assessed by urinary neopterin. Trans Roy. Soc. Trop. Med. Hyg. 1990; 84: 583-584.
65. Denz H, Fuchs D, Hausen A, Huber H, Nachbaur D, Reibnegger G, Thaler J, Werner ER, Wachter H. Value of urinary neopterin in the differential diagnosis of bacterial and viral infections. Klin. Wochenschr. 1990; 68: 218-222.
66. Dotevall L, Fuchs D, Reibnegger G, Wachter H, Hagberg L. Cerebrospinal fluid and serum neopterin levels in patients with Lyme neuroborreliosis. Infection 1990; 18: 210-214.
67. Hagberg L, Dotevall L, Norkrans G, Larsson M, Wachter H, Fuchs D. Cerebrospinal fluid neopterin concentrations in central nervous system infection. J. Infect. Dis. 1993; 168: 1285-1288.
68. Zaknun D, Zaknun J, Unsinn K, Wachter H, Fuchs D. Interferon-gamma-induced formation of neopterin and degradation of tryptophan in cerebrospinal fluid of children with meningitis but not with febrile convulsions. Pteridines 1994; 5: 102-106.
69. Reibnegger G, Egg D, Fuchs D, Günther R, Hausen A, Werner ER, Wachter H. Urinary neopterin refelects clinical activity in patients wich rheumatoid arthritis. Arthritis Rheum. 1986; 29: 102-106.
70. Märker-Alzer D, Diemer O, Strümper R, Rohe M. Neopterin production in inflamed joints: high levels in synovial fluids. Rheumatol. Int. 1986; 6: 151-154.
71. Leohirun L, Thuvasethakul P, Sumethkul V, Pholcharoen T, Boonpucknavig V. Urinary neopterin in patients with systemic lupus erythematosus. Clin. Chem. 1991; 37: 47-50.
72. Lim KL, Jones AC, Brown NS, Powell RJ. Urine neopterin as a parameter of disease activity in patients with systemic lupus erythematosus: Comparisons with serum sIL-2R and antibodies to dsDNA, erythrocyte sedimentation rate, and plasma C3, C4, and C3 degradation products. Ann. Rheum. Dis., 1993; 52: 429-435.
73. Samsonov MY, Tilz GP, Egorova O, Reibnegger G, Balabanova RM, Nassonov EL, Nassonova VA, Wachter H, Fuchs D. Serum soluble markers of immune activation and disease activity in systemic lupus erythematosus. Lupus 1995; 4: 29-32.
74. Nassonov EL, Samsonov MY, Tilz GP, Beketova TV, Semenkova EN, Baranov A, Wachter H, Fuchs D. Serum concentrations of neopterin, soluble interleukin-2 receptor, and soluble TNF-receptor in Wegeners granulomatosis. J. Rheumatol 1997; 24: 666-670.
75. Samsonov MY, Nassonov EL, Tilz GP, Gekht BM, Demel U, Gurkina GT, Shtutman VZ, Guseva AG, Wachter H, Fuchs D. Elevated serum levels of neopterin in adult patients with polymyositis/dermatomyositis. Brit. J. Rheumatol. 1997; 36: 656-660.
76. Reibnegger G, Bollbach R, Fuchs D, Hausen A, Judmaier G, Prior C, Rotthauwe HW, Werner ER, Wachter H. A simple index relating clinical activity in Crohns disease with T-cell activation: Hematokrit, frequency of liquid stools an urinary neopterin as parameters. Immunobiology 1986; 173: 1-11.
77. Niederwieser D, Fuchs D, Hausen, Judmaier G, Reibnegger G, Wachter H, Huber C. Neopterin as a new biochemical marker in the clinical asessment of ulcerative colitis. Immunobiology 1985; 170: 320-326.
78. Fuchs D, Granditsch G, Hausen A, Reibnegger G, Wachter H. Urinary neopterin excretion in coeliac disease. Lancet 1983; ii: 463-464.
79. Prior C, Frank A, Fuchs D, Hausen A, Judmaier G, Reibnegger G, Werner ER, Wachter H. Immunity in sarcoidosis. Lancet 1987: ii: 741.
80. Blaschke E., Eklund A, Persson U. Relationship between serum neopterin and lymphocytic alveolitis in sarcoidosis. Sarcoidosis 1988; 5: 25-30.
81. Samsonov M, Fuchs D, Reibnegger G, Belenkov JN, Nassonov EL, Wachter H. Y. Patterns of serological markers for cellular immune activation in patients with dilated cardiomyopathy and chronic myocarditis. Clin. Chem. 1992; 38: 678-680.
82. Iizuka T, Minatogawa Y, Suzuki H, Itoh M, Nakamine S, Hatanaka Y, Uemura S, Koike M. Urinary neopterin as a predictive marker of coronary artery abnormalities in Kawasaki Syndrome. Clin. Chem. 1993; 39/4:600-604.
83. Samsonov M, Tilz GP, Pisklakov VP, Reibnegger G, Nassonov EL, Nassonova VA, Wachter H, Fuchs D. Serum-soluble receptors for tumor necrosis factor-alpha and interleukin-2, and neopterin in acute rheumatic fever. Clin. Immunol. Immunopathol. 1995; 74: 31-34.
84. Melichar B, Gregor J, Solichova D, Lukes J, Ticky M, Pidrman V. Increased urinary neopterin in acute myocardial infarction. Clin. Chem. 1994; 40: 338-339.
85. Murr C, Fuith LC, Widner B, Wirleitner B, Baier-Bitterlich G, Fuchs D. Increased neopterin concentrations in patients with cancer: indicator of oxidative stress? Anticanc. Res., in press.
86. Aulitzky W, Frick J, Fuchs D, Hausen A, Reibnegger G, Wachter H. Significance of urinary neopterin in patients with malignant tumors of the genitourinary tract Cancer 1985; 55: 1052-1055.
87. Reibnegger G, Bichler A, Dapunt O, Fuchs D, Fuith LC, Hausen A, Hetzel H, Lutz H, Werner ER, Wachter H. Neopterin as a prognostic indicator in patients with carcinoma of the uterine cervix. Cancer Res. 1986; 46: 950-955.
88. Reibnegger G, Hetzel H, Fuchs D, Fuith LC, Hausen A, Werner ER, Wachter H. Clinical significance of neopterin for prognosis and follow-up in ovarian cancer Cancer Res. 1987; 47: 4977-4981.
89. Lewenhaupt A, Ekman P, Eneroth P, Eriksson A, Nilson B, Nordström L. Serum levels of neopterin as related to the prognosis of human prostatic carcinoma. Eur. Urol. 1986; 12: 422-425.
90. Kawasaki H, Watanabe H, Yamada S, Watanabe K, Suyama A. Prognostic significance of urinary neopterin levels in patients with hepatocellular carcinoma. Tohoku J. Exp. Med. 1988; 155: 311-318.
91. Denz H, Grünewald K, Thaler J, Huber H, Fuchs D, Hausen A, Reibnegger G, Werner ER, Wachter H. Urinary neopterin as a prognostic marker in haematological neoplasias. Pteridines 1989; 1: 167-170.
92. Weiss G, Kronberger P, Conrad F, Bodner E, Wachter H, Reibnegger G. Neopterin and prognosis in patients with adenocarcinoma of the colon. Cancer Res. 1993; 53: 260-265.
93. Kronberger P, Weiss G, Tschmelitsch J, Fuchs D, Salzer GM, Wachter H, Reibnegger G. Predictive value of urinary neopterin in patients with lung cancer Eur. J. Clin. Chem. Clin. Biochem. 1995; 33: 831-837.
94. Murr C, Berchtold J, Norer B, Waldhart E, Wachter H, Fuchs D. Neopterin as a prognostic parameter in patients with squamos cell carcinomas of the oral cavity. Int. J. Cancer 1998; 79: 476-480.
95. Margreiter R, Fuchs D, Hausen A, Huber C, Reibnegger G, Spielberger M, Wachter H. Neopterin as a new biochemical marker for diagnosis of allograft rejection. Transplantation 1983; 36: 650-653.
96. Havel M, Laczkovics A, Teufelsbauer H, Müller MM, Wolner E. Neopterin as a new marker to detect acute rejection after heart transplantation. J. Heart Transplant. 1989; 8: 167-170.
97. Dewitte JD, Bourbigot B, Berthou F, Airiau J, Cledes J, Floch HH. Early predictive value of urinary neopterin in kidney transplant rejection. Med. Sci. Res. 1987; 15: 271-272.
98. Reibnegger G, Aichberger C, Fuchs D, Hausen A, Spielberger M, Werner ER, Margreiter R, Wachter H. Posttransplant neopterin excretion in renal allograft recipients - a reliable diagnostic aid for acute rejection and a predictive marker of long-term graft survival. Transplantation 1991; 52: 58-63.
99. Tilg H, Margreiter R, Scriba M, Marth C, Niederwieser D, Aulitzky W, Spielberger M, Wachter H, Huber C. Clinical presentation of CMV infection in solid organ transplant recipients and its impact on graft rejection and neopterin excretion. Clin. Transplantation 1987; 1: 37-43.
100. Müller T, Keuchel M, Schindler S, Steinmetz A, Feiber H, Lange H. Differential diagnosis of transplant function disorders in therapy with monoclonal antibodies OKT3. Helv. Chir. Acta. 1991; 58: 271-275.
101. Hausen A, Aichberger C, Konigsrainer A, Weiss G, Margreiter R, Wachter H. Biliary and urinary neopterin concentrations in monitoring liver-allograft recipients. Clin. Chem. 1993; 39: 45-47.
102. Königsrainer A, Reibnegger G, Ofner D, Klima G, Tauscher T, Margreiter R. Pancreatic juice neopterin excretion: reliable marker for detection of pancreatic allograft rejection. Transplant. Proc. 1990; 22: 671-672.
103. Niederwieser D, Huber C, Gratwohl A, Bannert P, Fuchs D, Hausen A, Reibnegger G, Speck B, Wachter H. Neopterin as a new biochemical marker in the clinical monitoring of bone marrow transplant recipients. Transplantation 1984; 38: 497-500.
104. Reissigl H, Rosmanith P, Schönitzer D. HIV antigen study. Beitr. Infusionsther. 1989; 24: 14-17.
105. Hönlinger M, Fuchs D, Hausen A, Reibnegger G, Schönitzer D, Werner ER, Reissigl H, Dierich MP, Wachter H. Serum-Neopterin Bestimmung zur zusätzlichen Sicherung der Bluttransfusion. Deutsch. Med. Wochenschr. 1989; 114: 172-176.
106. Hönlinger M, Fuchs D, Hausen A, Reibnegger G, Schönitzer D, Werner ER, Reissigl H, Dierich MP, Wachter H. Neopterin screening and acute cytomegalovirus infections in blood donors. Clin. Investig. 1992; 70: 63.
107. Schennach H, Mayersbach P, Schönitzer D, Fuchs D, Wachter H, Reibnegger G. Increased prevalence of IgM antibodies to Epstein-Barr virus and parvovirus B19 in blood donations with above normal neopterin concentrations. Clin. Chem. 1994; 40: 2104-2105.
108. Schennach H, Schönitzer D, Fuchs D. Association between chronic hepatitis C virus infection and increased neopterin concentrations in in blood donations. Clin. Chem. 1998; 44: 2225-2226.